Bone toxicity is a well-known side effect of several antiviral agents. In a cohort of virologically suppressed HIV-infected patients, we investigated the effects of a lamivudine/dolutegravir dual therapy on bone mineral density (BMD). We observed a significant improvement in lumbar spine BMD as well as T-score after 12 months of observation with concomitant bisphosphonate therapy independently predicting a greater improvement. These preliminary data show a favorable effect of this 2-drug regimen on bone health.
Ciccullo, A., D'Avino, A., Lassandro, A. P., Baldin, G., Borghetti, A., Dusina, A., Emiliozzi, A., Gagliardini, R., Moschese, D., Belmonti, S., Lombardi, F., Di Giambenedetto, S., Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice, <<LE INFEZIONI IN MEDICINA>>, 2019; 26 (4): 336-340 [http://hdl.handle.net/10807/140090]
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice
Ciccullo, Arturo;Baldin, Gianmaria;Dusina, Alex;Emiliozzi, Arianna;Moschese, Davide;Lombardi, Francesca;Di Giambenedetto, Simona
2018
Abstract
Bone toxicity is a well-known side effect of several antiviral agents. In a cohort of virologically suppressed HIV-infected patients, we investigated the effects of a lamivudine/dolutegravir dual therapy on bone mineral density (BMD). We observed a significant improvement in lumbar spine BMD as well as T-score after 12 months of observation with concomitant bisphosphonate therapy independently predicting a greater improvement. These preliminary data show a favorable effect of this 2-drug regimen on bone health.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
